Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $35.71.

DAWN has been the topic of a number of research reports. Bank of America lowered their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th.

Day One Biopharmaceuticals Trading Up 0.4 %

Shares of DAWN opened at $12.26 on Tuesday. The firm has a market cap of $1.24 billion, a PE ratio of -11.90 and a beta of -1.46. The company’s 50 day simple moving average is $12.47 and its 200-day simple moving average is $13.53. Day One Biopharmaceuticals has a 12-month low of $11.13 and a 12-month high of $18.07.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Turn Management LLC acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth $13,204,000. GSA Capital Partners LLP acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth $825,000. Algert Global LLC raised its stake in shares of Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after buying an additional 50,990 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $866,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after buying an additional 64,700 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.